TY - JOUR
T1 - Improving the management of vaso-occlusive episodes in the pediatric emergency department
AU - Kavanagh, Patricia L.
AU - Sprinz, Philippa G.
AU - Wolfgang, Tahlia L.
AU - Killius, Kelly
AU - Champigny, Maria
AU - Sobota, Amy
AU - Dorfman, David
AU - Barry, Karan
AU - Miner, Renee
AU - Moses, James M.
N1 - Publisher Copyright:
Copyright © 2015 by the American Academy of Pediatrics.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - OBJECTIVES: Vaso-occlusive episodes (VOEs) account for the majority of emergency department (ED) visits for children with sickle cell disease (SCD). We hypothesized that addressing key barriers to VOE care would improve receipt of analgesics and outcomes. METHODS: A quality improvement (QI) initiative was conducted from September 2010 to April 2014 to streamline VOE care in an urban pediatric ED. Four interventions were used: a standardized time-specific VOE protocol; intranasal fentanyl as the first parenteral pain medication; an SCD pain medication calculator; and provider and patient/family education. Data were collected for 3 outcome measures (mean time from triage to first parenteral opioid and admission/discharge decision, and proportion discharged from the ED); 1 process measure (mean time from triage to initiation of patient-controlled analgesia); and 4 balancing measures (mean time from triage to second intravenous opioid dose, 24-hour ED readmission, respiratory depression, and length of stay). RESULTS: There were 289 ED visits in the study period. Improvements were seen in mean time to: first dose of parenteral opioid (56 to 23 minutes); second opiate intravenous dose (106 to 83 minutes); admission and discharge decisions (163 to 109 minutes and 271 to 178 minutes, respectively); and initiation of patientcontrolled analgesia (216 to 141 minutes). The proportion discharged from the ED increased from 32% to 48% (x2 = 6.5402, P = .01). No increase in 24-hour readmission, respiratory depression, or inpatient length of stay was observed. CONCLUSIONS: Using VOE-specific interventions, we significantly improved VOE care for children. Studies are needed to determine if these results can be replicated.
AB - OBJECTIVES: Vaso-occlusive episodes (VOEs) account for the majority of emergency department (ED) visits for children with sickle cell disease (SCD). We hypothesized that addressing key barriers to VOE care would improve receipt of analgesics and outcomes. METHODS: A quality improvement (QI) initiative was conducted from September 2010 to April 2014 to streamline VOE care in an urban pediatric ED. Four interventions were used: a standardized time-specific VOE protocol; intranasal fentanyl as the first parenteral pain medication; an SCD pain medication calculator; and provider and patient/family education. Data were collected for 3 outcome measures (mean time from triage to first parenteral opioid and admission/discharge decision, and proportion discharged from the ED); 1 process measure (mean time from triage to initiation of patient-controlled analgesia); and 4 balancing measures (mean time from triage to second intravenous opioid dose, 24-hour ED readmission, respiratory depression, and length of stay). RESULTS: There were 289 ED visits in the study period. Improvements were seen in mean time to: first dose of parenteral opioid (56 to 23 minutes); second opiate intravenous dose (106 to 83 minutes); admission and discharge decisions (163 to 109 minutes and 271 to 178 minutes, respectively); and initiation of patientcontrolled analgesia (216 to 141 minutes). The proportion discharged from the ED increased from 32% to 48% (x2 = 6.5402, P = .01). No increase in 24-hour readmission, respiratory depression, or inpatient length of stay was observed. CONCLUSIONS: Using VOE-specific interventions, we significantly improved VOE care for children. Studies are needed to determine if these results can be replicated.
UR - http://www.scopus.com/inward/record.url?scp=84942908868&partnerID=8YFLogxK
U2 - 10.1542/peds.2014-3470
DO - 10.1542/peds.2014-3470
M3 - Article
C2 - 26391933
AN - SCOPUS:84942908868
SN - 0031-4005
VL - 136
SP - e1016-e1025
JO - Pediatrics
JF - Pediatrics
IS - 4
ER -